| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41409-018-0158-9 |
| P698 | PubMed publication ID | 29549292 |
| P50 | author | Cornelis N De Jong | Q59692299 |
| P2093 | author name string | Jürgen Kuball | |
| Ellen Meijer | |||
| Marleen Schiffler | |||
| Reinier Raymakers | |||
| Mar Bellido | |||
| Eefke Petersen | |||
| Suzanne van Dorp | |||
| Marijke van Dijk | |||
| Liane Te Boome | |||
| Moniek de Witte | |||
| Inger Nijhof | |||
| Brigitte Bär | |||
| Lotte van der Wagen | |||
| Marieke Schoordijk | |||
| P2860 | cites work | National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 |
| National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report | Q35085226 | ||
| Ibrutinib treatment ameliorates murine chronic graft-versus-host disease | Q35140097 | ||
| The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study | Q35193763 | ||
| Rituximab for steroid-refractory chronic graft-versus-host disease | Q35848933 | ||
| Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell t | Q36212392 | ||
| Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. | Q36407176 | ||
| A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation | Q36471247 | ||
| Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. | Q36652772 | ||
| Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation | Q36700499 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells | Q37015691 | ||
| Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease | Q37511121 | ||
| Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis | Q37574510 | ||
| Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? | Q37737152 | ||
| Nilotinib: a novel, selective tyrosine kinase inhibitor | Q37855073 | ||
| Rituximab-based first line treatment for chronic GVHD after allogeneic SCT: results of a phase 2 study | Q38597157 | ||
| Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. | Q38863489 | ||
| Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis | Q38885564 | ||
| Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre t | Q38925520 | ||
| CD5+ B cells and the immune system | Q40385856 | ||
| Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. | Q40458599 | ||
| Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. | Q40843566 | ||
| Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial | Q42654326 | ||
| Imatinib for refractory chronic graft-versus-host disease with fibrotic features. | Q46031486 | ||
| Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. | Q46397677 | ||
| Ibrutinib for chronic graft-versus-host disease after failure of prior therapy | Q46428638 | ||
| Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. | Q54465299 | ||
| Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease | Q80337229 | ||
| Rituximab as salvage therapy for refractory chronic GVHD | Q80709875 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| Chronic graft versus host disease | Q111329725 | ||
| P304 | page(s) | 1255-1262 | |
| P577 | publication date | 2018-03-16 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib | |
| P478 | volume | 53 |
Search more.